Karyopharm Therapeutics Inc..
KPTI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Karyopharm Therapeutics Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer and other diseases. Their lead drug, XPOVIO (selinexor), is an oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO is approved in the Uni...Show More
Better Health for All
0
No evidence available to assess Karyopharm Therapeutics Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Karyopharm Therapeutics Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
Karyopharm Therapeutics Inc. reported a CEO-to-median employee pay ratio of 11:1 for 2023.
1
The CEO's total compensation was $2,626,288, and the median employee pay was $234,684.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles to assess Karyopharm Therapeutics Inc. against any of the Fair Trade & Ethical Sourcing KPIs. While some articles mention internal codes of ethics, compliance programs, and expectations for vendors, they do not provide quantitative evidence regarding supplier certifications, audit frequencies, incident numbers, traceability, remediation speed, or the percentage of supplier contracts with enforceable ethical-sourcing clauses.
1
Therefore, no KPIs can be scored.
Honest & Fair Business
-10
Karyopharm Therapeutics has a comprehensive Code of Business Conduct and Ethics, which is distributed annually to all employees, officers, and directors, who must certify their receipt, understanding, and compliance.
1
The policy includes anonymous reporting channels via a compliance hotline and website, and explicitly states the company will not retaliate against those who report suspected violations, unless the report was knowingly false.
2
A record of all complaints and concerns received is provided to the Audit Committee each fiscal quarter.
3
The company's Corporate Governance Guidelines state that a majority of the Board members shall be independent directors, as determined under Nasdaq rules.
4
The Code of Business Conduct and Ethics prohibits the use of company funds for gifts or gratuities to government officials, except if compliant with law, insignificant, and not given in expectation of action.
5
It also explicitly prohibits bribes and kickbacks, and addresses the Foreign Corrupt Practices Act regarding payments to foreign government officials.
6
Kind to Animals
-70
Karyopharm Therapeutics conducts preclinical trials on animals, including in murine, ferret, and canine models for various compounds.
1
The company generated clinical data for verdinexor in canine lymphoma, with 58 dogs enrolled in a Phase 2 study.
2
There is no information provided regarding a formal policy to reduce or prohibit animal testing, nor any mention of ethical oversight or alternative methods. The company used 25,000-50,000 animals annually in 2022 and 2023. Karyopharm collaborated with Anivive Lifesciences, which licensed exclusive worldwide rights to verdinexor for companion animals.
3
The company has no public position on animal welfare legislation and is silent on industry standards.
No War, No Weapons
0
Based on the provided documents, there is no evidence to suggest that Karyopharm Therapeutics Inc. is involved in any activities related to arms manufacturing, military contracts, or conflict facilitation. The company's focus is on pharmaceutical research, development, and commercialization of drugs for cancer and other diseases
1
. The ESG summaries from 2021 and 2023 do not mention any involvement in activities related to war or weapons
2
,
3
. The company's grant-giving policies are focused on medical education and charitable donations related to its disease focus areas
4
. Therefore, there is insufficient evidence to provide a score other than zero for the 'No War, No Weapons' value. The company's business model is fundamentally neutral to this value.
Planet-Friendly Business
0
Karyopharm Therapeutics Inc. has published a 2023 ESG Report and a 2023 Environment, Social and Governance Report.
1
The company reuses packaging materials such as cardboard boxes, packing peanuts, and bubble wrap.
2
It recycles paper, hard plastic, and cardboard used in the lab, and has switched from plastic tape to paper tape for packing shipments.
3
The company uses compostable and recyclable materials in office kitchens and environmentally friendly cleaning products.
4
Energy-efficient lighting is used throughout its offices.
5
The U.S. headquarters building has electric vehicle charging stations.
6
Karyopharm partners with office supply vendors committed to sustainability efforts.
7
The company has a target for a 60% reduction in plastic by 2040
8
and is planning to add solar panels to the parking lots at its U.S. headquarters.
9
Respect for Cultures & Communities
0
No evidence available to assess Karyopharm Therapeutics Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Karyopharm Therapeutics Inc. states compliance with the EU-U.S. Data Privacy Framework (DPF) and previously Privacy Shield, which are recognized certifications for international data transfers.
1
The company's privacy policy indicates that data transfer between devices and systems is secure and encrypted.
2
There are no documented incidents of unauthorized data use.
3
Users are granted rights to access, correct, erase, and transfer their data, and the company states that data is retained only as necessary for the purpose of collection.
4
Karyopharm also mentions compliance with major privacy regulations such as GDPR and CCPA.
5
Zero Waste & Sustainable Products
0
No evidence available to assess Karyopharm Therapeutics Inc. on Zero Waste & Sustainable Products.